AU2023324893A1 — Adagrasib solid pharmaceutical compositions
Assigned to Mirati Therapeutics Inc · Expires 2025-03-13 · 1y expired
What this patent protects
Pharmaceutical compositions in solid form comprising adagrasib, suitable for oral dosage to treat subjects having cancer; as well as methods of manufacturing the compositions, and methods of treating cancer. In one embodiment, the present invention provides a pharmaceutical compo…
USPTO Abstract
Pharmaceutical compositions in solid form comprising adagrasib, suitable for oral dosage to treat subjects having cancer; as well as methods of manufacturing the compositions, and methods of treating cancer. In one embodiment, the present invention provides a pharmaceutical composition, in solid form, suitable for oral administration to a subject, including but not limited to a human subject, which comprises adagrasib or a salt thereof, wherein the solid pharmaceutical composition, comprises: adagrasib, microcrystalline cellulose, mannitol, crospovidone, colloidalsilicon dioxide and magnesium stearate; wherein the solid pharmaceutical composition is in the form of a tablet; and wherein the solid pharmaceutical composition further comprises a film coat.
Drugs covered by this patent
- Krazati (ADAGRASIB) · Bristol-Myers Squibb
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.